Viatris

Viatris ( (VTRS) ) has issued an update. S. GAAP net loss of $119 million. S. 9x, underscoring improved balance sheet strength and continued capital returns. Management attributed the quarter’s performance to disciplined commercial execution and pipeline progress, noting that first-half momentum supports increased confidence in full-year targets. By combining portfolio reshaping, including the Tyrvaya divestiture, with ongoing share repurchases and debt reduction, Viatris is positioning itself for more balanced operations in the second half of 2026 and signaling a focus on long-term value creation for both patients and shareholders.

00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page . Spark’s Take on VTRS Stock According to Spark, TipRanks’ AI Analyst, VTRS is a Neutral. VTRS scores slightly above average primarily because cash generation and balance-sheet refinancing provide financial flexibility, and the latest earnings call reinforced guidance with improving operational momentum (notably Greater China) and multiple upcoming catalysts. Offsetting these positives, the financial statements still show negative TTM net income and multi-year revenue drift, while valuation is constrained by a negative P/E despite a moderate dividend yield; technical signals remain broadly neutral.

To see Spark’s full report on VTRS stock, click here . , based in Pittsburgh, is a global healthcare company focused on pharmaceuticals, including branded and generic medicines. The company operates across developed and emerging markets, with notable exposure to Greater China, and emphasizes a diversified portfolio spanning brands and generics to serve patients worldwide. 61B For a thorough assessment of VTRS stock, go to TipRanks’ Stock Analysis page .